Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset
Abstract Introduction We assessed the risk factors and outcome of COVID-19 in patients with autoimmune rheumatic diseases(AIRD) who contracted infection while on background treatment with tofacitinib. Methods This is a non-interventional, cross-sectional, questionnaire based telephonic study which i...
| Main Authors: | , , , , , , , , , , |
|---|---|
| 格式: | 文件 |
| 语言: | English |
| 出版: |
BMC
2023-07-01
|
| 丛编: | BMC Rheumatology |
| 主题: | |
| 在线阅读: | https://doi.org/10.1186/s41927-023-00345-8 |
| _version_ | 1827890151703969792 |
|---|---|
| author | Pramod Chebbi Vineeta Shobha Vijay K Rao Vikram Haridas Ramya Janardana Benzeeta Pinto Sharath Kumar Abhishek Patil Roopa Tekkatte Manasa Salanke K M Mahendranath |
| author_facet | Pramod Chebbi Vineeta Shobha Vijay K Rao Vikram Haridas Ramya Janardana Benzeeta Pinto Sharath Kumar Abhishek Patil Roopa Tekkatte Manasa Salanke K M Mahendranath |
| author_sort | Pramod Chebbi |
| collection | DOAJ |
| description | Abstract Introduction We assessed the risk factors and outcome of COVID-19 in patients with autoimmune rheumatic diseases(AIRD) who contracted infection while on background treatment with tofacitinib. Methods This is a non-interventional, cross-sectional, questionnaire based telephonic study which included consecutive AIRD patients on tofacitinib co-treatment. Data related to the AIRD subset, disease modifying anti rheumatic drugs(DMARDs) including glucocorticoids and comorbidities, was collected from 7 rheumatology centers across Karnataka during the second wave of COVID-19 pandemic. The information about COVID-19 occurrence and COVID-19 vaccination was recorded. Results During the study period (Jun-July 2021), 335 AIRD patients (80.6% female) on treatment with tofacitinib were included. The mean duration of tofacitinib use was 3.4+/-3.1months. Thirty-six(10.75%) patients developed COVID-19. Diabetes mellitus (p = 0.04 (OR 2.60 (1.13–5.99)) was identified as a risk factor for COVID-19 in our cohort. Almost half of our cohort was COVID-19 vaccinated with at least one dose, with resultant decline in incidence of COVID-19(OR 0.15 (0.06–0.39) among the vaccinated. Recovery amongst COVID-19 infection group was 91.2%. Conclusions The subset of AIRD patients who were on treatment with tofacitinib were found to have a higher rate of COVID-19 infection as compared to our KRACC cohort. Pre-existing comorbidity of diabetes mellitus was the significant risk factor in our cohort. This subset of the KRACC cohort shows RA patients had a lesser infection and PsA patients had a higher infection. |
| first_indexed | 2024-03-12T21:05:37Z |
| format | Article |
| id | doaj.art-0777ee33392f46a492e7174745cedd1e |
| institution | Directory Open Access Journal |
| issn | 2520-1026 |
| language | English |
| last_indexed | 2024-03-12T21:05:37Z |
| publishDate | 2023-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Rheumatology |
| spelling | doaj.art-0777ee33392f46a492e7174745cedd1e2023-07-30T11:26:56ZengBMCBMC Rheumatology2520-10262023-07-01711610.1186/s41927-023-00345-8Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subsetPramod Chebbi0Vineeta Shobha1Vijay K Rao2Vikram Haridas3Ramya Janardana4Benzeeta Pinto5Sharath Kumar6Abhishek Patil7Roopa Tekkatte8Manasa Salanke9K M Mahendranath10Department of Rheumatology, SDMCMSH, SDM University DharwadDepartment of Clinical Immunology and Rheumatology, St.John’s Medical college HospitalDepartment of Rheumatology, Manipal HospitalArthritis Superspeciality CenterDepartment of Clinical Immunology and Rheumatology, St.John’s Medical college HospitalDepartment of Clinical Immunology and Rheumatology, St.John’s Medical college HospitalOPTIMA Rheumatology & Arthritis clinicDepartment of Rheumatology, Manipal HospitalAster RV hospitalChanRe Rheumatology and Immunology CentreSamarpan Health centerAbstract Introduction We assessed the risk factors and outcome of COVID-19 in patients with autoimmune rheumatic diseases(AIRD) who contracted infection while on background treatment with tofacitinib. Methods This is a non-interventional, cross-sectional, questionnaire based telephonic study which included consecutive AIRD patients on tofacitinib co-treatment. Data related to the AIRD subset, disease modifying anti rheumatic drugs(DMARDs) including glucocorticoids and comorbidities, was collected from 7 rheumatology centers across Karnataka during the second wave of COVID-19 pandemic. The information about COVID-19 occurrence and COVID-19 vaccination was recorded. Results During the study period (Jun-July 2021), 335 AIRD patients (80.6% female) on treatment with tofacitinib were included. The mean duration of tofacitinib use was 3.4+/-3.1months. Thirty-six(10.75%) patients developed COVID-19. Diabetes mellitus (p = 0.04 (OR 2.60 (1.13–5.99)) was identified as a risk factor for COVID-19 in our cohort. Almost half of our cohort was COVID-19 vaccinated with at least one dose, with resultant decline in incidence of COVID-19(OR 0.15 (0.06–0.39) among the vaccinated. Recovery amongst COVID-19 infection group was 91.2%. Conclusions The subset of AIRD patients who were on treatment with tofacitinib were found to have a higher rate of COVID-19 infection as compared to our KRACC cohort. Pre-existing comorbidity of diabetes mellitus was the significant risk factor in our cohort. This subset of the KRACC cohort shows RA patients had a lesser infection and PsA patients had a higher infection.https://doi.org/10.1186/s41927-023-00345-8Autoimmune rheumatic diseasesSARS-CoV-2 infectionCovid-19Concomitant tofacitinib treatment |
| spellingShingle | Pramod Chebbi Vineeta Shobha Vijay K Rao Vikram Haridas Ramya Janardana Benzeeta Pinto Sharath Kumar Abhishek Patil Roopa Tekkatte Manasa Salanke K M Mahendranath Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset BMC Rheumatology Autoimmune rheumatic diseases SARS-CoV-2 infection Covid-19 Concomitant tofacitinib treatment |
| title | Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset |
| title_full | Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset |
| title_fullStr | Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset |
| title_full_unstemmed | Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset |
| title_short | Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset |
| title_sort | occurrence and outcome of covid 19 in aird patients on concomitant treatment with tofacitinib results from kra covid cohort kracc subset |
| topic | Autoimmune rheumatic diseases SARS-CoV-2 infection Covid-19 Concomitant tofacitinib treatment |
| url | https://doi.org/10.1186/s41927-023-00345-8 |
| work_keys_str_mv | AT pramodchebbi occurrenceandoutcomeofcovid19inairdpatientsonconcomitanttreatmentwithtofacitinibresultsfromkracovidcohortkraccsubset AT vineetashobha occurrenceandoutcomeofcovid19inairdpatientsonconcomitanttreatmentwithtofacitinibresultsfromkracovidcohortkraccsubset AT vijaykrao occurrenceandoutcomeofcovid19inairdpatientsonconcomitanttreatmentwithtofacitinibresultsfromkracovidcohortkraccsubset AT vikramharidas occurrenceandoutcomeofcovid19inairdpatientsonconcomitanttreatmentwithtofacitinibresultsfromkracovidcohortkraccsubset AT ramyajanardana occurrenceandoutcomeofcovid19inairdpatientsonconcomitanttreatmentwithtofacitinibresultsfromkracovidcohortkraccsubset AT benzeetapinto occurrenceandoutcomeofcovid19inairdpatientsonconcomitanttreatmentwithtofacitinibresultsfromkracovidcohortkraccsubset AT sharathkumar occurrenceandoutcomeofcovid19inairdpatientsonconcomitanttreatmentwithtofacitinibresultsfromkracovidcohortkraccsubset AT abhishekpatil occurrenceandoutcomeofcovid19inairdpatientsonconcomitanttreatmentwithtofacitinibresultsfromkracovidcohortkraccsubset AT roopatekkatte occurrenceandoutcomeofcovid19inairdpatientsonconcomitanttreatmentwithtofacitinibresultsfromkracovidcohortkraccsubset AT manasasalanke occurrenceandoutcomeofcovid19inairdpatientsonconcomitanttreatmentwithtofacitinibresultsfromkracovidcohortkraccsubset AT kmmahendranath occurrenceandoutcomeofcovid19inairdpatientsonconcomitanttreatmentwithtofacitinibresultsfromkracovidcohortkraccsubset |